Company ProfilePremium

Apollo Hospitals Enterprise Limited

Company Profile Analysis

Tickers: APOLLOHOSP.NS, 508869.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Apollo Hospitals Enterprise Limited - Company showcase

Year Founded & Workforce

1979

Apollo Hospitals Enterprise Limited logo

Apollo Hospitals Enterprise Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Apollo Hospitals Enterprise Limited Overview

Apollo Hospitals Enterprise is India's largest private healthcare group by revenue and the country's most vertically integrated one. It spans tertiary and quaternary hospitals, India's largest retail pharmacy network (7,100+ stores), India's largest pharmaceutical wholesale supply chain (through the pending Keimed combination), the Apollo 24/7 digital platform, and an out-of-hospital network of clinics, diagnostics, day-surgery, dialysis and dental formats. The hospital business, about 50% of revenue, is the profit and cash engine: roughly 24% EBITDA margins and 25%+ ROCE. The pharmacy and digital arm drives scale and patient acquisition at thin but improving margins. Apollo's moat is brand, clinical depth in complex specialties, and an integrated care pathway. The group is mid-way through a structural reset: it is demerging pharmacy and digital into Apollo Healthtech Limited (listing targeted for Q4 FY27) while running its largest-ever hospital capacity build (about 5,800 beds over five years). That will leave AHEL as a hospital-centric compounder holding a 15% stake in the pharmacy/digital vehicle.


What the company does

AHEL operates a pan-India network of multi-specialty and super-specialty hospitals. As of Q3 FY26 this comprised 76 hospitals with about 9,561 operational beds including managed facilities (FundsIndia equity research desk). Owned-and-operated census beds excluding AHLL and managed beds were 8,131 at end-FY26 and 8,352 at 30 June 2026, with 70% group occupancy in Q1 FY27 (company Q1 FY27 disclosures via Omnicuris/IPP). Around the hospitals sit two businesses that are housed in subsidiaries and consolidated:

  1. Apollo HealthCo Limited (AHL) — omnichannel pharmacy distribution (back-end supply to the 7,100+ Apollo Pharmacy stores, owned by the separately held front-end company Apollo Pharmacies Ltd) and the Apollo 24/7 digital platform (teleconsultation, e-pharmacy, diagnostics booking, insurance distribution). FY26 revenue: INR 10,808 crore, the first year above INR 10,000 crore.

  2. Apollo Health and Lifestyle Limited (AHLL) — retail healthcare and diagnostics: Apollo Clinics, Apollo Diagnostics, Apollo Sugar, Apollo Spectra (short-stay surgery), Apollo Dialysis and Apollo White Dental. Apollo Cradle (maternity) and Apollo Fertility are being divested to Cloudnine. FY26 revenue: INR 1,865 crore. AHLL became a 100% subsidiary in April 2026 after the IFC stake buyout.

Business and revenue model

Revenue streamModel typePrimary payor / customerApproximate share of FY26 consolidated revenue (derived)
Inpatient and outpatient hospital servicesFee-for-service (episodic)Self-pay (cash), private insurance/TPA, corporates, government schemes (CGHS/ECHS/PMJAY/state), international patients50% (INR 12,555 crore)
Pharmacy distribution (offline back-end)Product distribution / tradingApollo Pharmacies Ltd front-end stores (B2B intra-group) and, post-Keimed, third-party pharmaciesMajority of the 43% HealthCo share
Apollo 24/7 digitalPlatform / marketplace (GMV-based take rates), consultation fees, insurance commissionsConsumers, insurersSmall (online pharmacy distribution revenue was INR 326 crore in Q2 FY26)
Diagnostics and retail health (AHLL)Fee-for-service, B2C retailConsumers, corporates, referral doctors7% (INR 1,865 crore)

Apollo is overwhelmingly a service business (hospitals, clinics, diagnostics) with a large product-distribution adjunct (pharmacy). It has no material licensing or subscription revenue. Health-check packages (ProHealth) and Apollo 24/7 memberships are quasi-subscription but not separately disclosed.

Payor mix. In Q4 FY25, cash and insurance patients contributed about 83% of inpatient revenue, and revenue from that segment grew 11% YoY (ICICI Direct Q4 FY25 note). International patients are a meaningful high-ARPOB cohort. Bangladesh historically accounted for about 30% of international revenue but only about 2% of total revenue (ICICI Direct Q1 FY25).

Value-chain position

Apollo sits at the care-delivery end of the healthcare value chain (hospitals, clinics, diagnostics) and the distribution/retail end of the pharmaceutical chain (wholesale distribution via Keimed, retail via Apollo Pharmacy, online via 24/7). It does not manufacture drugs or devices at scale. Its private-label Apollo-branded FMCG/OTC range is sourced from contract manufacturers; private label was about 16% of pharmacy revenue in Q1 FY25 per the earnings call. Integration lets Apollo capture margin across referral (24/7, clinics) → diagnosis (AHLL) → intervention (hospitals) → chronic medication (pharmacy).

Company's own description vs. independent characterisation

The company describes itself in investor communications as India's first corporate hospital and Asia's foremost integrated healthcare provider, present across hospitals, pharmacies, primary care and diagnostic clinics, and multiple retail health formats (Screener company profile, drawing on company material). Management frames the current strategy as moving from episodic treatment to a continuum connecting prevention, early diagnosis, advanced intervention and long-term care (Q1 FY27 commentary, IPP, Aug 2026).

Independent characterisation. On economic substance Apollo is two businesses joined by a brand:

  • a high-return, capital-intensive hospital operator — about 24% EBITDA margin, ROCE 25–28%, ARPP of about INR 1.73 lakh per inpatient in Q2 FY26, the same profile as Max/Fortis/Medanta;

  • a low-margin, high-volume pharmacy distribution and consumer-health platform — HealthCo EBITDA margin 5.8% in Q1 FY27, which compares with pharmacy retailers and distributors such as MedPlus and Entero.

The consolidated 15% EBITDA margin understates hospital quality and overstates platform profitability. This blend is why the HealthCo demerger is the defining corporate event of FY27.

End-markets served

End-marketApollo vehicleGeography
Tertiary/quaternary hospital care (cardiac, oncology, neuro, gastro, ortho, transplant)AHEL and hospital subsidiaries (e.g., Apollo Multispeciality Hospitals, Kolkata)India, with metros the core
Medical value travelAHEL International Patient ServicesPatients from South Asia, Africa, Middle East, South-East Asia
Retail pharmacy and pharma wholesale distributionApollo HealthCo / Apollo Pharmacies / KeimedPan-India; 19,000+ pincodes online
Digital healthApollo 24/7Pan-India; 46 million users (Basis Point Insight, Mar 2026)
Diagnostics and ambulatory careAHLLPan-India; 3,328 out-of-hospital touchpoints (Q3 FY26)
Health insurance distributionApollo 24/7 (insurance distribution started FY25)India

Strategy

Stated strategic themes (paraphrased from FY26–Q1 FY27 communications)

  1. Hospital capacity and complexity. Add about 5,800 beds over five years (about INR 11,150 crore capex), focused on metros and the CONGO specialties (Cardiac, Oncology, Neuro, Gastro, Ortho) plus transplants. Push a higher share of complex procedures and international patients.

  2. Value unlocking through simplification. Demerge and list omnichannel pharmacy and digital as Apollo Healthtech; take AHLL to 100% ownership; exit non-core verticals (Cradle and Fertility to Cloudnine); merge Apollo Hospitals North into AHEL.

  3. Care continuum. Management frames growth around non-communicable diseases and moving from episodic treatment to prevention, early diagnosis, intervention and chronic care.

  4. Digital profitability. Apollo 24/7 reached cash breakeven around Q1 FY27; full breakeven including ESOP costs targeted for Q3 FY27.

  5. Capital efficiency. HCS ROCE of 25–28%; consolidated ROCE 23.7%; AAA credit profile.

Initiative register (last 24 months)

DateInitiativeDetail / target
Apr 2024Advent investment in Apollo HealthCoINR 2,475 crore CCPS (12.1%); funds Keimed integration and digital
May 2025Board-approved hospital expansion planBengaluru 700 beds; Gurgaon 510; Pune 400; Sonarpur 270; Hyderabad brownfield; earlier framing about 4,300 beds / INR 7,600 crore
Jun 2025Composite Scheme for Apollo HealthtechDemerger plus Keimed merger; AHEL retains 15%; swap ratio 195.2 AHTL shares per 100 AHEL shares
Sep 2025AHLL full ownershipINR 1,254 crore to IFC; completed Apr 2026
Sep 2025Gurugram proton oncology centre100 beds; INR 570 crore; about 4-year build; Apollo's third proton facility
FY25–FY26Apollo 24/7 cost programme24/7 costs cut about 20% YoY in Q1 FY26; quarterly cost INR 124 crore in Q3 FY26 (incl. INR 38 crore ESOP), down from INR 141 crore; digital cash loss INR 10 crore in Q1 FY27
FY25AHLL cost programmeAbout INR 60 crore cost reduction cited by Q2 FY26
FY26Four new hospitalsAbout 855 beds
May 2026Cloudnine combinationCradle and Fertility valued at INR 1,550 crore (cash plus 9.9% of combined entity)
May 2026Merger of Apollo Hospitals North into AHELNCLT route; 10–12 months
Aug 20265,800-bed five-year planAbout INR 11,150 crore capex
ESGSustainability commitmentsSee Section 20

Management medium-term targets and guidance

Guidance itemTargetSource
FY27 Healthcare Services revenue growthAbout 18–20% (existing hospitals 13–14%, new hospitals about 7%)Q1 FY27 call (Quartr; Stockgro)
FY27 Healthcare Services EBITDA marginAt least +100 bps improvementQ4 FY26 call
Apollo HealthCo / AHTL annualised revenue run-rateINR 25,000 crore by Q4 FY27Q4 FY26 and Q1 FY27 calls
AHTL exit EBITDA margin6.5–7.0% by end-FY27Q4 FY26 and Q1 FY27 calls
Apollo 24/7 / insurance breakevenFull breakeven (incl. ESOP) by Q3 FY27Q1 FY27 call
AHTL listingQ4 FY27 (Jan–Mar 2027)Company; Sahi; Multibagg
Gurugram hospital commissioningQ3 FY27Q1 FY27 release
Bed additionsAbout 5,800 over five yearsQ1 FY27 release

Products & Services

Pricing is generally not publicly disclosed at the catalogue level. Hospital tariffs vary by city, room category and payor contract.

Healthcare Services (Hospitals)

OfferingDescription and capabilitiesTarget customerLaunch / latestPricing modelFlagship examples
Cardiac SciencesCardiology, interventional cardiology, CABG, valve, structural heart, heart transplantInsured and self-pay adults; internationalSince 1983Package and itemised fee-for-serviceApollo Chennai, Indraprastha Delhi, Jubilee Hills Hyderabad
OncologyMedical, surgical and radiation oncology; proton therapy; bone-marrow transplantCancer patients across payors; internationalProton: Jan 2019 (Chennai); Gurugram proton centre announced Sep 2025, about 4-year buildFee-for-service and packages; drug pricing subject to NPPA trade-margin capsApollo Proton Cancer Centre, Chennai; Apollo Cancer Centres network
NeurosciencesNeurosurgery, stroke, epilepsy, spineAdults/childrenOngoingFee-for-servicePan-network
Gastroenterology and hepatologyEndoscopy, GI surgery, liver transplantAdults/childrenOngoingFee-for-service/packagesChennai, Delhi, Hyderabad
OrthopaedicsJoint replacement, sports medicine, robotic arthroplastyAdultsOngoingPackages; knee implant prices regulated by NPPA ceilingPan-network
Transplant programmeKidney, liver, heart, lung, multi-organ; green-corridor coordinationComplex end-stage diseaseOngoing; multi-organ green-corridor cases reported Q4 FY26PackagesChennai, Delhi, Hyderabad, Bengaluru, Navi Mumbai, Lucknow
Robotic and minimally invasive surgeryRobotic urology, gynaecology, GI, orthoElective surgicalOngoingFee-for-servicePan-network
Critical careICU, NICU/PICU, emergency/traumaAll payorsOngoingPer-day plus proceduresPan-network
International Patient ServicesConcierge, visa, interpretation, packages for overseas patientsAfrica, Middle East, South-East Asia, SAARCOngoingPackagesHospital-agnostic
ProHealth / preventive health checksPersonalised preventive programmes, AI risk scoringCorporates, individualsProHealth programme relaunched about 2018–2023Fixed-price packagesAll hospitals
Remote TeleHealthTeleconsultation, tele-radiology, rural telemedicine, govt partnershipsGovt, corporates, remote populationsSince 2000Contract/feeTo be demerged into AHTL
O&M / project consultancyManaging third-party hospitalsHospital ownersOngoingManagement fees6 managed hospitals, 790 beds (Screener)
Medical educationNursing, allied health, academic programmesStudentsOngoingTuitionApollo academic institutions; not a reported segment
Healthcare Services KPIQ4FY25Q2FY26Q3FY26Q4FY26Q1FY27
Census beds owned excl. AHLL and managed (number)8,025—8,0728,1318,352
Group occupancy (%)6769676870
ARPOB (INR per day)63,569————
ARPP (INR per inpatient)—173,318———
HCS ROCE (%)———25.428.5

Operating KPIs.

Digital Health & Pharmacy Distribution (Apollo HealthCo)

OfferingDescriptionTarget customerLatest data pointPricing / model
Offline pharmacy distributionBack-end supply of pharma, OTC, private-label and FMCG to Apollo Pharmacy storesApollo Pharmacies Ltd (front-end)Q2 FY26 revenue INR 2,335 crore (+16%); Q4 FY26 distribution EBITDA INR 195 crore (+20%)Distribution margin
Apollo Pharmacy network (front-end, Apollo Pharmacies Ltd)India's largest pharmacy retail chainRetail consumers7,100+ stores (Mar 2026); 7,113 at Q3 FY26Retail MRP-based
Apollo 24/7 online pharmacyE-pharmacy with quick deliveryConsumers in 19,000+ pincodesQ2 FY26 online distribution revenue INR 326 crore (+22%)Retail MRP less discounts
Apollo 24/7 teleconsultationVideo/chat consults with Apollo doctorsConsumersPlatform GMV INR 528 crore in Q4 FY26 (+20%)Per-consult fee
Apollo 24/7 diagnostics marketplaceHome sample collection, lab bookingConsumersExpanded to 18 new cities (Q2 FY26)Per-test
Insurance distributionHealth insurance sold via the platformConsumersStarted FY25; breakeven targeted Q3 FY27Commission
Private label (Apollo brand)OTC, nutrition, personal careConsumersAbout 16% of pharmacy revenue (Q1 FY25)Retail
Apollo 24/7 Circle (membership)Loyalty/benefits programmeRepeat customers—Membership fee
Keimed wholesale distribution (post-scheme)Wholesale pharma distribution with about 100 distribution centres serving 70,000+ pharmaciesIndependent pharmacies, hospitalsAbout 15% share of India medicine distribution (Outlook Business)Wholesale margin

User base: 46 million Apollo 24/7 users (Basis Point Insight, Mar 2026). Platform GMV disclosures are inconsistent: one release cites INR 723 crore for Q2 FY26 against INR 528 crore for Q4 FY26, likely different GMV definitions. This is flagged.

Retail Health & Diagnostics (AHLL)

Brand / verticalDescriptionStatus
Apollo ClinicsMulti-specialty primary-care clinicsCore; scaling
Apollo DiagnosticsPathology labs and collection centresFastest-growing (+52% YoY in Q4 FY26); expanded tests (fetal chromosomal screening, genetic testing, extended HPV genotyping, whole genome sequencing)
Apollo SugarDiabetes management clinicsCore
Apollo SpectraShort-stay surgical hospitals (ambulatory)Core
Apollo DialysisDialysis centresCore
Apollo White DentalDental chainCore
Apollo CradleMaternity and newborn hospitals: 12 centres in Hyderabad, Bengaluru, Chennai, Delhi NCR, PunjabBeing combined into Cloudnine (announced 20 May 2026)
Apollo FertilityIVF/fertility centres (about 20 units per media)Being combined into Cloudnine

AHLL operated 3,328 out-of-hospital touchpoints at Q3 FY26.

Financial Narrative

Income statement

Sources and notes:

  • Revenue: company releases and Chola/Screener (FY22 INR 14,662.6 crore; FY23 INR 16,612.5 crore; FY24 INR 19,059.2 crore; FY25 INR 21,794 crore; FY26 INR 25,229 crore). FY21 base was INR 10,560 crore.

  • PAT: Stockezee/Screener; FY26 per company. EPS basic FY22–FY25 from Screener. FY26 basic is derived (INR 1,942 crore / 143.78 million shares); FY26 diluted INR 134.95 per IndiaMedToday.

  • FY22 PAT included one-off gains linked to restructuring (exceptional items). Underlying FY22 profit was lower.

  • FY24 EBITDA is derived from FY25 reported INR 3,022 crore and +26%.

Gross profit: Apollo reports under Ind AS by nature of expense and does not disclose gross profit. Simply Wall St computes TTM gross profit of about INR 8,300 crore on INR 24,220 crore revenue (about 34%); this is a third-party construct.

  • Quarterly PBT (before exceptional items) for FY26 was INR 569 crore (Q1), INR 668 crore (Q2) and INR 686 crore (Q3) per 5paisa.

  • DPS: FY24 = INR 6 interim + INR 10 final; FY25 = INR 9 interim + INR 10 final; FY26 = INR 10 interim + INR 10 final (total FY26 payout INR 287.6 crore).

Revenue CAGR. FY22–FY26 (4 years) is 14.5% (derived). FY21–FY26 (5 years, from INR 10,560 crore) is 19.0% (derived), inflated by the COVID-depressed FY21 base.

Commentary. Revenue has compounded at a steady 13–16% for four years. The real inflection is in profitability: consolidated EBITDA margin expanded about 230 bps from FY24 to FY26 and PAT grew 61% in FY25 and 34% in FY26. Three drivers stand out:

  • Apollo 24/7 cost reduction: digital cash loss fell to INR 10 crore in Q1 FY27 against losses above INR 140 crore a quarter in FY25.

  • Operating leverage in pharmacy distribution.

  • Steady hospital margins of about 24% despite new-unit start-up losses (INR 41 crore in Q4 FY26).

FY23–FY24 were margin-trough years as 24/7 investment peaked; FY25–FY26 show the payoff.

Balance sheet

Sources and discrepancies:

  • Total assets and PP&E: Stockopedia (INR million, converted). Goodwill, cash, receivables, inventory and lease-inclusive debt: stockanalysis.com. Borrowings excluding leases, net debt excluding leases and NWC: Stockezee. Shareholders' funds and minority interest: MarketsMojo.

  • MarketsMojo shows FY26 long-term borrowings of INR 2,705 crore against Stockezee's INR 2,430 crore (FY25: INR 4,754 crore vs INR 4,417 crore). Total borrowings agree at INR 5,658–5,659 crore.

  • The FY26 jump in short-term borrowings (INR 858 crore to INR 3,228 crore) mainly reflects reclassification of long-term debt into the current portion. Stockanalysis shows current portion of long-term debt at about INR 3,228 crore. This implies a meaningful FY27 refinancing need.

Commentary. Leverage rose in FY25: borrowings excluding leases climbed from INR 3,162 crore to INR 5,275 crore to fund hospital asset acquisitions (Pune, Kolkata Sonarpur, Gurgaon, Bengaluru) and AHLL/HealthCo needs. Leverage then stabilised in FY26 despite the INR 1,254 crore IFC buyout of AHLL, helped by 34% higher operating cash flow. Equity has compounded about 14% a year. Advent's INR 2,475 crore CCPS in Apollo HealthCo is treated as equity by CRISIL, which cushions group gearing.

Cash flow

Source: stockanalysis.com (INR million, converted). Stockezee reports FY22 OCF of INR 1,616 crore against stockanalysis' INR 1,696 crore. Capex is derived as OCF minus FCF. Dividends paid are derived from per-share cash payouts in each fiscal year × 143.78 million shares. No buyback has been announced or executed in the period.

Commentary. OCF rose 34% in FY26 to INR 2,856 crore, a cash conversion of about 76% of EBITDA. FCF is thin relative to profits because Apollo is in a heavy capex phase (INR 1,700–2,000 crore a year). Capex will step up under the 5,800-bed plan (about INR 11,150 crore over five years, roughly INR 2,200 crore a year before acquisitions). CRISIL expects AHEL's standalone cash surplus to run at INR 1,800–2,000 crore a year, enough to fund most expansion internally.

Ratios

ROE, ROA, gearing, coverage and turnover are derived from the tables above; FY22 ROA uses closing assets. ROIC is not disclosed by the company; consolidated ROCE excluding capital work-in-progress is the closest proxy (20% in FY24 to 23.7% in FY26, company release via ScanX). CRISIL estimated FY26 net debt/EBITDA at about 1.1x on its own adjusted basis. The negative cash conversion cycle reflects supplier credit in pharmacy distribution exceeding receivable days on insurer/government payors.

Commentary. Returns have re-rated sharply. ROE moved from about 14% in FY23–24 to 22% in FY26 as 24/7 losses fell and hospital ROCE climbed. Interest coverage nearly doubled. Gearing remains moderate and is on the AAA trajectory recognised by ICRA. The main watch-point is the FY26 shift of about INR 2,400 crore of debt into current maturities, a refinancing rather than solvency issue given AAA/A1+ access.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment (Reported Label) Overview

Segment (reported label)Operating vehicleContents

Healthcare Services (HCS)

AHEL standalone plus hospital subsidiaries/JVs (e.g., Apollo Multispeciality Hospitals, Apollo Hospitals North, Apollomedics Lucknow; associate Indraprastha Medical Corp)

Owned and managed hospitals, remote telehealth (to be demerged), project consultancy, O&M contracts

Digital Health & Pharmacy Distribution

Apollo HealthCo Ltd (AHEL about 78.87% per Wikipedia; Advent 12.1% via CCPS)

Back-end distribution to Apollo Pharmacy stores, Apollo 24/7 platform, online pharmacy, insurance distribution

Retail Health & Diagnostics

Apollo Health and Lifestyle Ltd (100% from Apr 2026)

Clinics, diagnostics, sugar clinics, Spectra, dialysis, dental; Cradle and Fertility pending divestment

Segment revenue (INR Cr)

Segment revenue (INR Cr)FY2024FY2025FY2026

Healthcare Services revenue (INR Cr)

9,86511,14712,555

Apollo HealthCo revenue (INR Cr)

7,8399,09310,808

AHLL revenue (INR Cr)

1,3631,5541,865

Consolidated revenue (INR Cr)

19,05921,79425,229

Segment Margins & Growth (%) and Revenue by Segment (%)

Segment metricFY2024FY2025FY2026

Healthcare Services YoY growth (%)

—1313

Apollo HealthCo YoY growth (%)

—1619

AHLL YoY growth (%)

—1420

Healthcare Services share of consolidated revenue (%)

51.851.149.8

Apollo HealthCo share of consolidated revenue (%)

41.141.742.8

AHLL share of consolidated revenue (%)

7.27.17.4

Segment EBITDA (INR Cr)

Segment EBITDA (INR Cr)FY2024FY2025FY2026

Healthcare Services EBITDA (INR Cr)

2,3492,7013,063

Apollo HealthCo EBITDA post 24/7 costs and ESOP (INR Cr)

—168493

AHLL EBITDA (INR Cr)

117154213

Consolidated EBITDA (INR Cr)

2,3983,0223,769

Segment EBITDA margin (%)

Segment EBITDA margin (%)FY2024FY2025FY2026

Healthcare Services EBITDA margin (%)

23.824.224.4

Apollo HealthCo EBITDA margin (%)

—1.84.6

AHLL EBITDA margin (%)

8.69.911.4

Consolidated EBITDA margin (%)

12.613.914.9

Results by Segment

Segment PAT (INR Cr)FY2025Q1 FY26Q1 FY27

Healthcare Services PAT (INR Cr)

1,426384480

Apollo HealthCo PAT (INR Cr)

—57101

AHLL PAT (INR Cr)

-27—-1

Results by Segment (Q1FY26–Q1FY27)

Quarterly metricQ1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Consolidated revenue (INR Cr)

5,8426,3046,4776,6057,043

Healthcare Services revenue (INR Cr)

2,9353,1693,1833,2683,567

Apollo HealthCo revenue (INR Cr)

2,4722,6612,8272,8482,977

AHLL revenue (INR Cr)

435474467489499

Consolidated EBITDA (INR Cr)

8529419651,0111,092

Healthcare Services EBITDA (INR Cr)

718——781862

Apollo HealthCo EBITDA (INR Cr)

94110—156171

AHLL EBITDA (INR Cr)

40——7559

Consolidated PAT attributable (INR Cr)

433477502529581

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

14,66316,61219,05921,79425,229

Revenue YoY growth (%)

38.913.314.714.315.8

EBITDA company-reported (INR Cr)

——2,3983,0223,769

EBITDA margin (%)

——12.613.914.9

Screener operating margin OPM (%)

15121314—

Net profit attributable to owners (INR Cr)

1,0568198991,4461,942

Net margin (%)

7.24.94.76.67.7

EPS basic (INR)

73.4256.9762.50100.56135.07

EPS diluted (INR)

————134.95

Dividend per share declared (INR)

——161920

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (INR Cr)

13,26914,42816,75320,65722,197

Net PP&E incl. right-of-use (INR Cr)

7,2898,0349,38510,58712,030

Goodwill (INR Cr)

9409861,0121,0311,032

Cash and short-term investments (INR Cr)

1,0487261,1902,0102,133

Long-term borrowings (INR Cr)

2,4271,9382,2364,4172,430

Short-term borrowings (INR Cr)

2087739268583,228

Total borrowings excl. leases (INR Cr)

2,6362,7103,1625,2755,659

Total debt incl. lease liabilities (INR Cr)

4,0684,3325,3337,8648,493

Net debt incl. leases (INR Cr)

3,0203,6074,1435,8546,360

Net debt excl. leases (INR Cr)

2,0532,2772,6564,6974,847

Shareholders' funds (INR Cr)

5,6236,1976,9358,2129,480

Minority interest (INR Cr)

280334385441494

Trade receivables (INR Cr)

1,9502,4982,8123,3613,674

Inventory (INR Cr)

432390460481542

Net working capital (INR Cr)

1,7381,0126152,450419

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (INR Cr)

1,6961,3771,9202,1362,856

Capital expenditure (INR Cr)

6571,1291,1371,7121,962

Free cash flow (INR Cr)

1,039248783424894

Cash acquisitions (INR Cr)

10150401,300

Investing cash flow (INR Cr)

-847-871-1,537-3,381-2,148

Financing cash flow (INR Cr)

-792-633-3111,317-478

Net debt issued or repaid (INR Cr)

-493-1282251,88790

Interest paid (INR Cr)

255251303302278

Income tax paid (INR Cr)

204382467486606

Dividends paid derived (INR Cr)

——216273288

Share buybacks (INR Cr)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE on average equity (%)

20.713.913.719.122.0

ROA on average assets (%)

8.05.95.87.79.1

ROCE consolidated excl. CWIP company-reported (%)

——20.0—23.7

ROCE Screener (%)

17141517—

Debt to equity excl. leases (x)

0.470.440.460.640.60

Net debt to EBITDA incl. leases (x)

——1.731.941.69

Net debt to EBITDA excl. leases (x)

——1.111.551.29

Interest coverage EBITDA to interest paid (x)

——7.910.013.6

Asset turnover on average assets (x)

—1.201.221.171.18

Cash conversion cycle Screener (days)

-12-14-16-23-6

Region revenue (INR Cr)

Region revenue (INR Cr)FY2024FY2025FY2026

India consolidated revenue (INR Cr)

19,05921,79425,229

India YoY growth (%)

14.714.315.8

Cluster Datapoint Details

Cluster datapoint (Q3 FY26)Value

Eastern region revenue growth YoY

+15% (IP volume +6%, ARPP +10% to INR 1,54,408; occupancy 76%)

Highest-ARPP cluster cited

INR 2,02,804 at 68% occupancy across 1,355 beds

Cluster with weakest occupancy cited

51% occupancy (ARPP INR 1,66,264)

Group occupancy

67% vs 68% a year earlier, with 8,072 operating beds

Datapoint Details

DatapointValueSource / date

Last price

INR 7,739.50

NSE, 19 Oct 2026 1:02 pm (ad-hoc-news)

52-week range

INR 6,696.50 – 9,070.50

ad-hoc-news, Oct 2026 (Anand Rathi high INR 9,326.80)

1-year return

About +3.2%

Anand Rathi, 7 Oct 2026

3-year return

About +77.3%

Equentis, as of 10 Apr 2026

5-year return

About +139.8%

Equentis, as of 10 Apr 2026

10-year return

About +448%

Equentis, as of 10 Apr 2026

Beta

About 0.8 (Equentis); Tickertape describes volatility at 1.70x Nifty

Sources differ

Valuation Multiples

MultipleApolloBasis

Market cap (INR Cr)

111,282

143.78 million shares

Enterprise value (INR Cr)

118,136

Market cap + net debt incl. leases (INR 6,360 crore) + minority (INR 494 crore)

P/E TTM (x)

53.2

TTM attributable PAT about INR 2,090 crore

EV/EBITDA TTM (x)

29.5

TTM EBITDA about INR 4,009 crore

EV/Sales TTM (x)

4.5

TTM revenue INR 26,430 crore

P/B (x)

11.7

FY26 shareholders' funds INR 9,480 crore

Analyst Ratings & Targets

BrokerDateRatingTarget (INR)

Jefferies

2 Oct 2026

Buy

10,350

Nomura

Aug 2025

Neutral

—

Simply Wall St aggregated consensus target

Date not specified (stale)

—8,793.5

ICICI Direct

2026

Buy (long-term)

—

Dividend metric

Dividend metricFY2022FY2023FY2024FY2025FY2026

Interim dividend per share (INR)

——6910

Final dividend per share (INR)

11.759101010

Total dividend per share (INR)

——161920

Payout ratio on attributable PAT (%)

——25.618.914.8

Credit Ratings

AgencyEntityRatingOutlookDate

ICRA

AHEL (INR 3,000 crore term loans/unallocated)

AAA / A1+

Stable

Assigned 12–18 May 2026

CRISIL

AHEL (INR 2,800 crore bank facilities; INR 19 crore NCDs)

AA+ / A1+

Positive (revised from Stable, 27 Jan 2026)

Reaffirmed; credit bulletin 29 May 2026

CRISIL

Apollo HealthCo

AA- / A1+

Watch Developing

Jan 2026

CRISIL

AHLL

AA-

Positive (upgraded from A+)

27 Jan 2026

CRISIL

Apollo Multispeciality Hospitals

AA+ / A1+

Positive

27 Jan 2026

CRISIL

Apollo Hospitals North

AA / A1+

Watch Positive

May 2026

Moody's / S&P / Fitch

AHEL

Not rated (not publicly disclosed)

——

Analyst Conclusions

Management guidance (FY27)

Management has guided to:

  • Hospital revenue growth of about 18–20%, with at least 100 bps of HCS margin expansion.

  • An Apollo HealthCo/AHTL annualised revenue run-rate of INR 25,000 crore with a 6.5–7% exit EBITDA margin by Q4 FY27.

  • Apollo 24/7 full breakeven by Q3 FY27.

  • Gurugram commissioning in Q3 FY27.

  • AHTL listing in Q4 FY27.

Q1 FY27 delivered against this trajectory: HCS +22%, HealthCo EBITDA margin 5.8%, digital cash loss INR 10 crore.

Consensus growth expectations

Simply Wall St's analyst-consensus narrative (date unspecified) assumed about 17.5% annual revenue growth and a 9.1% profit margin by 2029. Q1 FY27 revenue of INR 7,044 crore beat consensus of INR 6,886 crore (ad-hoc-news).

Bull case

  1. Pure-play re-rating. After demerger, AHEL becomes a hospital company with about 24–25% EBITDA margins and 25%+ ROCE plus a 15% stake in AHTL. Hospital peers trade at 60–66x P/E against Apollo's consolidated about 53x, so the blended-margin discount could close.

  2. Earnings visibility from capacity. Census beds grew from 8,025 (Mar 2025) to 8,352 (Jun 2026) and are heading towards about 13,100. With established hospitals growing 13–14% plus about 7% from new hospitals, high-teens HCS growth can persist for several years.

  3. HealthCo operating leverage. Quarterly EBITDA went from INR 36 crore (Q4 FY25) to INR 171 crore (Q1 FY27). Hitting a 6.5–7% margin on an INR 25,000 crore run-rate implies about INR 1,600–1,750 crore of annualised AHTL EBITDA, more than three times FY26's derived INR 493 crore.

Bear case

  1. Regulatory compression. The NPPA oncology 30% trade-margin cap and Supreme Court scrutiny of hospital mark-ups directly hit pharmacy and consumable margins in Apollo's most complex specialty. Further caps on consumables or room/package pricing could erode the 24% HCS margin.

  2. Execution overload. Simultaneously building 5,800 beds (about INR 11,150 crore), completing a three-way scheme, closing Cloudnine and merging AHNL stretches management. Start-up losses and refinancing of about INR 3,200 crore of current debt add risk.

  3. Valuation and governance. At about 53x TTM P/E and 11.7x P/B the stock prices in success. Promoter selling (Aug 2025), a modest 28% promoter stake, and related-party optics in the Keimed merger could cap multiples.

Key catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
27 Oct 2026Supreme Court hearing on drug and consumable mark-ups
5 Nov 2026Q2 FY27 results: HCS growth vs 18–20% guidance; HealthCo margin; digital breakeven
Nov 2026NPPA notification of the oncology trade-margin cap (covered drugs, effective date)
Q3 FY27 (Oct–Dec 2026)Gurugram hospital commissioning; Apollo 24/7 full breakeven
Q3–Q4 FY27NCLT final sanction of the composite scheme; Cloudnine closing
Q4 FY27 (Jan–Mar 2027)Apollo Healthtech listing; AHEL receives 15% stake; shareholders receive 195.2 AHTL shares per 100 AHEL
FY27Refinancing of current borrowings; ICRA/CRISIL surveillance (possible CRISIL upgrade given Positive outlook)
QuarterlyOccupancy (70% in Q1 FY27), ARPOB/ARPP, new-unit losses, international patient trends, promoter pledge and shareholding

Analyst verdict

Apollo Hospitals enters the second half of FY27 at the strongest operating point in its 43-year history. Consolidated revenue is running at about INR 28,000 crore annualised. Q1 FY27 growth of 21% was the fastest in several years. Consolidated EBITDA margins have widened about 230 bps in two years, and the balance sheet now carries the sector's only AAA rating. The improvement is broad: hospitals re-accelerated from single-digit growth to 22% as new capacity ramped, AHLL is compounding at about 20% with expanding margins, and Apollo HealthCo has turned from a cash drain into a contributor as Apollo 24/7 losses were nearly eliminated.

The investment debate is therefore less about operating quality than about structure, regulation and price. Structurally, the Apollo Healthtech demerger is the key value-realisation event. It separates a 24%-margin, 25%-ROCE hospital franchise from a mid-single-digit-margin distribution platform, and lets each be valued on its own terms. The cost is that the integration moat must now survive arm's-length contracts, and timing has already slipped once. On regulation, India's renewed push on oncology drug margins and hospital mark-ups is the most material external risk and is live within weeks. On price, about 53x trailing earnings and about 29x EV/EBITDA leave limited room for execution missteps across a 5,800-bed build.

Our synthesis is constructive on fundamentals and neutral-to-positive on timing. The earnings trajectory, credit quality and demerger optionality justify a premium to the Indian market. Near-term upside depends on clean delivery of the Q2–Q3 FY27 digital breakeven, Gurugram commissioning, and a contained outcome from the NPPA and Supreme Court proceedings. Investors should treat pricing-policy clarity in November 2026 and the AHTL listing in Q4 FY27 as the two gating events for a sustained re-rating toward pure-play hospital multiples.


APPENDIX — PRINCIPAL SOURCES CONSULTED

  • Apollo Hospitals Q4 FY26 earnings call transcript (apollohospitals.com, May 2026) — FY26 and Q4 figures, segment data, guidance

  • Apollo Hospitals Q2 FY26 earnings call transcript (apollohospitals.com, Nov 2025) — Q2 FY26 KPIs

  • Apollo Hospitals Q4 FY25 call (AlphaStreet transcript) and FY25 release (mediacdn.apollohospitals.com) — FY25 segment data

  • NSE filing: hospital expansion corrigendum (31 May 2025) — Expansion plan

  • NSE filing: Cloudnine press release (20 May 2026) — Divestment terms

  • NSE filing: ICRA rating letter (19 May 2026); ICRA rationale (18 May 2026) — Credit rating

  • CRISIL rating rationales (27 Jan 2026) and credit bulletin (29 May 2026) — Ratings, AHLL/Apollo Medicals transactions, AHNL merger

  • IIFL directors' report extract (composite scheme) — Scheme structure

  • Quartr Q1 FY27 and Q4 FY26 summaries; Kotak Neo; IPP (Indian Pharma Post); PTI via HDFC Sky; Stockgro — Q1 FY27 results and guidance

  • Alpha Spread / Yahoo Finance Q4 FY26 call; BW Healthcare World; Multibagg; Whalesbook; Investywise; ScanX — FY26 results, NCLT timeline, dividends

  • Outlook Business; HDFC Sky; Basis Point Insight; Sahi — Demerger terms and timeline

  • Business Standard; ICICI Direct research notes; FundsIndia; EY healthcare newsletters (Jan and Jul 2026) — Analyst views, capacity, industry context

  • Upstox; MarketsMojo; Emkay/Dion; Univest; Voguestock (shareholding) — Ownership

  • stockanalysis.com; Stockopedia; Stockezee; Screener; MarketsMojo (financial statements) — Five-year financials

  • Anand Rathi; Value Research; Fyers; Equentis; ICICI Direct; ad-hoc-news (Oct 2026) — Price, valuation, peers

  • Medical Dialogues; Outlook India; The South First; Moneylife (Oct 2026) — NPPA oncology cap, Supreme Court proceedings

  • Company press releases on Dr. Madhu Sasidhar's appointment (Mar 2024); Becker's Hospital Review — Leadership

  • Wikipedia (Apollo Hospitals; Indraprastha Apollo Hospital) — Historical milestones (secondary)

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / backgroundEducationAge

Dr. Prathap C. Reddy

Founder & Executive Chairman

Founded Apollo 1983; cardiologist; Padma Vibhushan

MBBS (Stanley Medical College); US cardiology training

About 93 (b. 1933, per public biographies)

Ms. Preetha Reddy

Executive Vice Chairperson

Long-standing executive director; formerly Managing Director

—

Not disclosed here

Ms. Shobana Kamineni

Executive Vice Chairperson; Executive Chairperson of Apollo HealthCo; proposed Executive Chairperson of Apollo Healthtech Ltd upon NCLT sanction

Leads pharmacy/digital; former CII President

—

Not disclosed here

Ms. Suneeta Reddy

Managing Director

MD of AHEL; leads finance and strategy

—

Not disclosed here

Dr. Sangita Reddy

Joint Managing Director; Chairperson of AHLL

Former FICCI President; digital health and telemedicine lead

—

Not disclosed here

Dr. Madhu Sasidhar

President & CEO, Hospitals Division

Joined Oct 2023 as Chief Strategy Officer; CEO since Mar 2024. Previously 16 years at Cleveland Clinic, including President of Tradition Hospital and CMO of Cleveland Clinic Abu Dhabi

MBBS (JIPMER); Internal Medicine (St Luke's-Roosevelt, New York); Pulmonary and Critical Care fellowships (Yale); Global Executive MBA (INSEAD)

—

Mr. Krishnan Akhileswaran

Group Chief Financial Officer

Long-tenured CFO

——

Mr. S. M. Krishnan

Senior Vice President – Finance & Company Secretary

Signatory on NSE/BSE filings

——

Mr. Sriram Iyer

CEO, Apollo Health and Lifestyle Ltd

Named on FY25–FY26 earnings calls

——

“—” = not publicly disclosed.

Board & Management Changes

DateChangeContext

Oct 2023

Dr. Madhu Sasidhar joins as Chief Strategy Officer

Planned succession for hospital leadership

Mar 2024

Sasidhar named President & CEO, Hospitals; Dr. K. Hari Prasad retires

Professionalisation of hospital operations

May–Jun 2026

Shobana Kamineni proposed as Executive Chairperson of Apollo Healthtech Ltd, effective on NCLT sanction

Governance of demerged NewCo

Shareholding Trend

Holder category (% of equity)Jun2025Sep2025Dec2025Mar2026Jun2026

Promoter and promoter group (%)

29.3428.0228.0228.0228.02

Foreign institutional investors (%)

43.4944.2043.5442.6241.5

Mutual funds (%)

15.9416.4816.7516.65—

Other domestic institutions (%)

5.414.654.756.11—

Total DII (%)

———22.7623.72

Retail and others (%)

5.836.666.946.60—

Major Shareholders

HolderShares (lakh)% stake

PCR Investments Ltd (promoter entity)

272.2318.93

Ms. Suneeta Reddy

29.372.04

Government of Singapore (largest public shareholder)

—2.34

Dr. Sangita Reddy

24.331.69

Ms. Shobana Kamineni

22.401.56

Mr. K. Vishweshwar Reddy

15.771.10

Competitive Landscape

Competitors by Segment

SegmentCompetitorPositioning vs Apollo

Hospitals

Max Healthcare Institute

Highest-margin listed peer (about 27% EBITDA, ARPOB about INR 77,900); North India-centric; aggressive expansion

Hospitals

Fortis Healthcare

Pan-India; owns Agilus diagnostics; about 24% hospital margin (Q2 FY26)

Hospitals

Narayana Health

Value-cost model; Cayman and UK operations; strong ROE

Hospitals

Global Health (Medanta)

NCR/Lucknow/Patna; ARPOB about INR 62,000

Hospitals

Aster DM Healthcare / Quality Care India

Post-merger South India platform; revenue +18% FY26

Hospitals

Manipal Hospitals

Large Bengaluru/East footprint; appears as a listed peer in Fyers data (Sep 2026)

Hospitals

KIMS Hospitals

South India; expanding

Hospitals

HCG (oncology)

Oncology-focused competitor in Bengaluru and beyond

Pharmacy retail

MedPlus Health Services

Listed omnichannel pharmacy chain

Pharmacy retail

Wellness Forever, Tata 1mg, PharmEasy, Netmeds (Reliance), Amazon Pharmacy

Online and offline competitors to Apollo Pharmacy and 24/7

Pharma distribution

Entero Healthcare and regional distributors

Competitors to Keimed

Diagnostics

Dr Lal PathLabs, Metropolis, Agilus (Fortis), Thyrocare

Competitors to Apollo Diagnostics

Maternity

Cloudnine, Rainbow Children's Medicare, Motherhood

Apollo exiting via Cloudnine stake

Peer Comparison FY2026

MetricApollo HospitalsMax HealthcareFortis HealthcareNarayana Health

Market cap (INR Cr)

124,66195,86868,70137,993

TTM revenue (INR Cr)

26,4308,7129,5069,072

TTM net profit (INR Cr)

2,1271,4571,052824

Net margin (%)

8.016.411.09.1

ROE (%)

22.714.411.120.1

P/E (x)

60.566.465.847.1

Hospital EBITDA margin Q2 FY26 (%)

24.6272424

Consolidated EBITDA margin Q2 FY26 (%)

15272424

Company Snapshot

$2,913.3M

Revenue

1979

Founded

SWOT Analysis

Strengths

  • Scale leadership. FY26 consolidated revenue of INR 25,229 crore is the first above INR 25,000 crore for an Indian healthcare provider and about 2.8x Fortis's TTM revenue.
  • High-return hospital core. HCS EBITDA margin was 24.4% in FY26 and HCS ROCE was 28.5% in Q1 FY27.
  • Profit momentum. PAT compounded 61% (FY25) and 34% (FY26). Q1 FY27 PAT rose 34% YoY to INR 581 crore.
  • Credit strength. ICRA AAA (Stable)/A1+ (May 2026), the first for an Indian hospital company, and CRISIL AA+/Positive.
  • Integrated distribution moat. 7,100+ pharmacies, about 100 Keimed distribution centres serving 70,000+ pharmacies, and 46 million Apollo 24/7 users.
  • Cash generation. OCF of INR 2,856 crore in FY26 (+34%) and interest coverage of about 13.6x (derived).

Weaknesses

  • Diluted consolidated margins. Consolidated EBITDA margin of 14.9% (FY26) against 24–27% at hospital pure-plays, because HealthCo ran at about 4.6% (derived residual).
  • ARPOB gap. About INR 63,569 (Q4 FY25) against about INR 77,900 at Max.
  • Thin free cash flow. FCF of INR 894 crore in FY26 (3.5% of revenue) during a heavy capex cycle.
  • Short-term debt concentration. Current borrowings rose to about INR 3,228 crore at FY26 from INR 858 crore.
  • Occupancy variance. Some clusters ran at about 51% occupancy in Q3 FY26 against 76% in the East.
  • Governance optics. Promoter holding fell to 28.02% after the Aug 2025 block sale (18.97 lakh shares), and some promoter shares remain pledged (2.49%).

Opportunities

  • Demerger value unlock. AHTL listing targeted for Q4 FY27; AHEL retains 15% and shareholders get 195.2 AHTL shares per 100 AHEL shares.
  • Capacity growth. About 5,800 beds over five years (about INR 11,150 crore capex), with census capacity potentially moving from about 9,561 to about 13,100.
  • Digital breakeven. Apollo 24/7 cash loss fell to INR 10 crore in Q1 FY27, with full breakeven targeted Q3 FY27.
  • HealthCo scale. INR 25,000 crore annualised run-rate and 6.5–7% exit margin targets for Q4 FY27.
  • Oncology leadership. Third proton centre at Gurugram (INR 570 crore).
  • Diagnostics growth. AHLL diagnostics +52% YoY (Q4 FY26), and AHLL margin up to 11.4% in FY26 from about 8.6% in FY24 (derived).

Threats

  • Oncology pricing. NPPA 30% trade-margin cap on non-scheduled anti-cancer drugs (in-principle, 8 Oct 2026), with MRP cuts of 20–70%.
  • Judicial scrutiny. The Supreme Court has questioned hospital mark-ups on stents and consumables; hearing 27 Oct 2026.
  • Competitive capacity. Peers plan about 34,000 beds; Max alone plans about 3,700 beds by FY28.
  • Demerger execution and timing. Listing has already slipped from about April 2026 to Q4 FY27.
  • International-patient geopolitics. Bangladesh decline cut HCS revenue by about 1% in Q2 FY26.
  • Valuation compression. The stock fell 8.7% in one week (28 Sep – 2 Oct 2026) and the P/E has drifted from about 60x to about 53x.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
30 May 2025FY25 results: revenue INR 21,794 crore (+14%), EBITDA INR 3,022 crore (+26%), PAT INR 1,446 crore (+61%); final dividend INR 10Margin inflection confirmed
31 May 2025Corrigendum to board-approved hospital expansion plan (Bengaluru 700 beds; Gurgaon, Pune, Sonarpur acquisitions)Capacity pipeline formalised
30 Jun 2025Composite Scheme for Apollo Healthtech approved by board; shares rose over 3%Defining value-unlock event
12 Aug 2025Q1 FY26: revenue INR 5,842 crore (+15%), EBITDA INR 852 crore (+26%); HCS +11%Brokers raised targets; Nomura Neutral
Aug 2025Promoter Suneeta Reddy sells about 18.97 lakh shares at INR 7,850Overhang; promoter stake to 28.02%
12 Sep 2025AHLL IFC-stake buyout (INR 1,254 crore) and Gurugram proton centre (INR 570 crore) approvedSimplification plus oncology
24 Sep 2025CCI approves composite schemeRegulatory milestone
6–7 Nov 2025Q2 FY26: revenue INR 6,304 crore (+13%), PAT INR 477 crore (+26%); HCS +9%; Bangladesh drag about 1%Hospital growth trough
24 Dec 2025BSE no-objection to scheme (NSE also issued)Exchange clearance
20 Jan 2026CCI approves AHEL's acquisition of IFC stake in AHLLClosing path cleared
27 Jan 2026CRISIL revises AHEL outlook to Positive; AHLL upgraded to AA-/PositiveCredit improvement
10 Feb 2026Q3 FY26: revenue INR 6,477 crore (+17%), PAT INR 502 crore; interim dividend INR 10Growth re-acceleration
Q3 FY26Pune 75 beds and Defence Colony 30 beds operationalisedCapacity ramp
20 Mar 2026Commentary frames demerger as recasting Apollo as a hospital pure-playInvestor narrative shift
26 Mar 2026NCLT Chennai order on scheme application (certified 9 Apr)Legal milestone
Apr 2026AHLL becomes 100% owned (residual shares INR 18.69 crore)Ownership consolidated
5 May 2026NCLT order revises stakeholder meeting dates to 24 Jun 2026Timeline reset; listing to Q4 FY27
12–18 May 2026ICRA assigns AAA (Stable)/A1+ on INR 3,000 crore facilitiesSector-first AAA
20 May 2026FY26 results: revenue INR 25,229 crore, EBITDA INR 3,769 crore, PAT INR 1,942 crore; final dividend INR 10 (FY26 total INR 20)Record year
20 May 2026Cradle and Fertility to Cloudnine (EV INR 1,550 crore; 9.9% stake)Portfolio pruning
20 May 2026Board approves merger of Apollo Hospitals North into AHELSimplification
May–Jun 2026Shobana Kamineni proposed as Executive Chairperson of AHTL (effective on NCLT sanction)NewCo governance
24 Jun 2026EGM and creditor meetings on composite scheme–
Jul 2026Stock trades near 52-week high (about INR 8,900–9,070)Re-rating on Q4/demerger
12 Aug 2026Q1 FY27: revenue INR 7,043 crore (+21%), EBITDA INR 1,092 crore (+28%, margin 15.5%), PAT INR 581 crore (+34%); 5,800-bed plan; Sarjapur 180 beds launchedStrongest growth quarter in years; beat consensus (INR 6,886 crore)
14 Aug 2026Record date for FY26 final dividendShareholder return
28 Sep – 2 Oct 2026Stock falls 8.7% in a week, against Sensex -3.2%De-rating amid pricing-policy risk
30 Sep 2026Apollo Hospitals Guwahati named "Hospital of the Year" at a News18 Assam conclaveBrand/clinical recognition
2 Oct 2026Jefferies Buy rating, target INR 10,350Sell-side support
8 Oct 2026NPPA in-principle 30% trade-margin cap on identified non-scheduled anti-cancer drugs (projected about INR 2,500 crore annual patient savings; MRP cuts of 20–70%)Regulatory headwind for oncology pharmacy margins
12 Oct 2026Government tells Supreme Court cancer-drug margins capped at 30%; Court questions hospital mark-ups on stents and consumables; next hearing 27 Oct 2026Broader hospital-pricing scrutiny
15 Oct 2026Company schedules Q2 FY27 earnings call for 5 Nov 2026Next catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Revenue by Segment: Healthcare Services revenue rose from INR 98.7 Bn in FY2024 to INR 125.6 Bn in FY2026.
Apollo Hospitals Enterprise Limited — Revenue by Segment
Series (INR Bn)FY2024FY2025FY2026
Healthcare Services revenue98.7111.5125.6
Apollo HealthCo revenue78.490.9108.1
AHLL revenue13.615.518.7
Consolidated revenue190.6217.9252.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.